Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review

Bruno Silva Andrade; Fernanda de Souza Rangel; Naiane Oliveira Santos; Andria Dos Santos Freitas; Wagner Rodrigues de Assis Soares; Sergio Siqueira; Debmalya Barh; Aristóteles Góes Neto; Alexander Birbrair; Vasco Ariston de Carvalho Azevedo

Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review

The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the prog...

Descripción completa

Detalles Bibliográficos
Autores:	Bruno Silva Andrade, Fernanda de Souza Rangel, Naiane Oliveira Santos, Andria Dos Santos Freitas, Wagner Rodrigues de Assis Soares, Sergio Siqueira, Debmalya Barh, Aristóteles Góes Neto, Alexander Birbrair, Vasco Ariston de Carvalho Azevedo
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2020
País:	Brasil
Institución:	Universidade Federal de Minas Gerais (UFMG)
Repositorio:	Repositório Institucional da UFMG
Idioma:	inglés
OAI Identifier:	oai:repositorio.ufmg.br:1843/55213
Acceso en línea:	https://doi.org/10.3389/fphar.2020.590598 http://hdl.handle.net/1843/55213 https://orcid.org/0000-0002-8031-9454 https://orcid.org/0000-0001-5138-9042 https://orcid.org/0000-0001-9041-9777 https://orcid.org/0000-0001-9254-6550 https://orcid.org/0000-0002-2557-7768 https://orcid.org/0000-0002-7692-6243
Access Level:	acceso abierto
Palabra clave:	SARS-CoV-2 Prophylaxis Antiviral Drug repurposing COVID-19 Antivirais Reposicionamento de Medicamentos

id	BR_27d5abbec5e3e9eabeb30b10efbbd2d2
oai_identifier_str	oai:repositorio.ufmg.br:1843/55213
network_acronym_str	BR
network_name_str	Brasil
repository_id_str
spelling	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic reviewReaproveitamento de medicamentos aprovados para orientar a profilaxia da COVID-19: uma revisão sistemáticaSARS-CoV-2ProphylaxisAntiviralDrug repurposingCOVID-19SARS-CoV-2AntiviraisReposicionamento de MedicamentosCOVID-19The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the progress of this viral infection, including pre-(PrEP) and post-exposure prophylaxis. On the other hand, research groups around the world are still studying novel drug prophylaxis and treatment using repurposing approaches, as well as vaccination options, which are in different pre-clinical and clinical testing phases. This systematic review evaluated 1,228 articles from the PubMed and Scopus indexing databases, following the Kitchenham bibliographic searching protocol, with the aim to list drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols. In searching protocol, we used the following keywords: “Covid-19 or SARS-CoV-2” or “Coronavirus or 2019 nCoV,” “prophylaxis,” “prophylactic,” “pre-exposure,” “COVID-19 or SARS-CoV-2 Chemoprophylaxis,” “repurposed,” “strategies,” “clinical,” “trials,” “anti-SARS-CoV-2,” “anti-covid-19,” “Antiviral,” “Therapy prevention in vitro,” in cells “and” human testing. After all protocol steps, we selected 60 articles that included: 15 studies with clinical data, 22 studies that used in vitro experiments, seven studies using animal models, and 18 studies performed with in silico experiments. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. The drugs selected in this review can assist clinical studies and medical guidelines on the rational repurposing of known antiviral drugs for COVID-19 prophylaxis.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorOutra AgênciaUniversidade Federal de Minas GeraisBrasilICB - DEPARTAMENTO DE MICROBIOLOGIAICB - DEPARTAMENTO DE PATOLOGIAUFMG2023-06-21T20:05:00Z2023-06-21T20:05:00Z2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdfhttps://doi.org/10.3389/fphar.2020.5905981663-9812http://hdl.handle.net/1843/55213https://orcid.org/0000-0002-8031-9454https://orcid.org/0000-0001-5138-9042https://orcid.org/0000-0001-9041-9777https://orcid.org/0000-0001-9254-6550https://orcid.org/0000-0002-2557-7768https://orcid.org/0000-0002-7692-6243engFrontiers in Pharmacologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGBruno Silva AndradeFernanda de Souza RangelNaiane Oliveira SantosAndria Dos Santos FreitasWagner Rodrigues de Assis SoaresSergio SiqueiraDebmalya BarhAristóteles Góes NetoAlexander BirbrairVasco Ariston de Carvalho Azevedo2023-06-21T20:05:00Zoai:repositorio.ufmg.br:1843/55213Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-06-21T20:05Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review Reaproveitamento de medicamentos aprovados para orientar a profilaxia da COVID-19: uma revisão sistemática
title	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
spellingShingle	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review Bruno Silva Andrade SARS-CoV-2 Prophylaxis Antiviral Drug repurposing COVID-19 SARS-CoV-2 Antivirais Reposicionamento de Medicamentos COVID-19
title_short	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
title_full	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
title_fullStr	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
title_full_unstemmed	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
title_sort	Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review
dc.creator.none.fl_str_mv	Bruno Silva Andrade Fernanda de Souza Rangel Naiane Oliveira Santos Andria Dos Santos Freitas Wagner Rodrigues de Assis Soares Sergio Siqueira Debmalya Barh Aristóteles Góes Neto Alexander Birbrair Vasco Ariston de Carvalho Azevedo
author	Bruno Silva Andrade
author_facet	Bruno Silva Andrade Fernanda de Souza Rangel Naiane Oliveira Santos Andria Dos Santos Freitas Wagner Rodrigues de Assis Soares Sergio Siqueira Debmalya Barh Aristóteles Góes Neto Alexander Birbrair Vasco Ariston de Carvalho Azevedo
author_role	author
author2	Fernanda de Souza Rangel Naiane Oliveira Santos Andria Dos Santos Freitas Wagner Rodrigues de Assis Soares Sergio Siqueira Debmalya Barh Aristóteles Góes Neto Alexander Birbrair Vasco Ariston de Carvalho Azevedo
author2_role	author author author author author author author author author
dc.subject.por.fl_str_mv	SARS-CoV-2 Prophylaxis Antiviral Drug repurposing COVID-19 SARS-CoV-2 Antivirais Reposicionamento de Medicamentos COVID-19
topic	SARS-CoV-2 Prophylaxis Antiviral Drug repurposing COVID-19 SARS-CoV-2 Antivirais Reposicionamento de Medicamentos COVID-19
description	The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the progress of this viral infection, including pre-(PrEP) and post-exposure prophylaxis. On the other hand, research groups around the world are still studying novel drug prophylaxis and treatment using repurposing approaches, as well as vaccination options, which are in different pre-clinical and clinical testing phases. This systematic review evaluated 1,228 articles from the PubMed and Scopus indexing databases, following the Kitchenham bibliographic searching protocol, with the aim to list drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols. In searching protocol, we used the following keywords: “Covid-19 or SARS-CoV-2” or “Coronavirus or 2019 nCoV,” “prophylaxis,” “prophylactic,” “pre-exposure,” “COVID-19 or SARS-CoV-2 Chemoprophylaxis,” “repurposed,” “strategies,” “clinical,” “trials,” “anti-SARS-CoV-2,” “anti-covid-19,” “Antiviral,” “Therapy prevention in vitro,” in cells “and” human testing. After all protocol steps, we selected 60 articles that included: 15 studies with clinical data, 22 studies that used in vitro experiments, seven studies using animal models, and 18 studies performed with in silico experiments. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. The drugs selected in this review can assist clinical studies and medical guidelines on the rational repurposing of known antiviral drugs for COVID-19 prophylaxis.
publishDate	2020
dc.date.none.fl_str_mv	2020 2023-06-21T20:05:00Z 2023-06-21T20:05:00Z
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.uri.fl_str_mv	https://doi.org/10.3389/fphar.2020.590598 1663-9812 http://hdl.handle.net/1843/55213 https://orcid.org/0000-0002-8031-9454 https://orcid.org/0000-0001-5138-9042 https://orcid.org/0000-0001-9041-9777 https://orcid.org/0000-0001-9254-6550 https://orcid.org/0000-0002-2557-7768 https://orcid.org/0000-0002-7692-6243
url	https://doi.org/10.3389/fphar.2020.590598 http://hdl.handle.net/1843/55213 https://orcid.org/0000-0002-8031-9454 https://orcid.org/0000-0001-5138-9042 https://orcid.org/0000-0001-9041-9777 https://orcid.org/0000-0001-9254-6550 https://orcid.org/0000-0002-2557-7768 https://orcid.org/0000-0002-7692-6243
identifier_str_mv	1663-9812
dc.language.iso.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	Frontiers in Pharmacology
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	pdf application/pdf
dc.publisher.none.fl_str_mv	Universidade Federal de Minas Gerais Brasil ICB - DEPARTAMENTO DE MICROBIOLOGIA ICB - DEPARTAMENTO DE PATOLOGIA UFMG
publisher.none.fl_str_mv	Universidade Federal de Minas Gerais Brasil ICB - DEPARTAMENTO DE MICROBIOLOGIA ICB - DEPARTAMENTO DE PATOLOGIA UFMG
dc.source.none.fl_str_mv	reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG
instname_str	Universidade Federal de Minas Gerais (UFMG)
instacron_str	UFMG
institution	UFMG
reponame_str	Repositório Institucional da UFMG
collection	Repositório Institucional da UFMG
repository.name.fl_str_mv	Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv	repositorio@ufmg.br
_version_	1853663200920207360
score	15,300719

Repurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic review

Similares en LA Referencia